Phase 4 N=20 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
Prediabetes · Obesity
Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=114 Diazepam Use With Standard Management for Acute Low Back Pain
Low Back Pain
Primary: Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire — 11; 11 units on a scale
Phase 3 N=1,230 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)
Herpes Zoster
Primary: Incidence of Confirmed Herpes-Zoster — 32.889; 91.883 Number of cases per 1000 person years
Phase 2 N=150 Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 5.9; 4.5 months
Phase 2 N=92 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose (MTD) of the Each Combination Agent Combined With a Fixed Dose of BAY 43-9006 Determined by Dose-limiting Toxicities (DLT) (Phase I) — 100; 25; NA…
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
N/A N=248 Evaluating the Effect of Acupuncture on Pain Relief Using Quantitative Sensory Testing (QST)
Pain
Primary: Heat Pain Tolerance - Baseline: Maximum Temperature (Heat) That Could be Tolerated by Participants — 49.9; 50.5; 49.9; 49.5 Degrees Celcius
Phase 2 N=31 Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
Depression · Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 3.47; 4.09; 16.93; 14.64 units on a scale
N/A N=11 Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
N/A N=441 Negative Pressure Wound Therapy in Cesarean Section
Postoperative Wound Complications
Primary: Number of Participants With Wound Complication — 37; 42 Participants — p=0.54
Phase 4 N=236 An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in One Second (FEV1) at Week 8 — 1.745; 1.692 Liters — p=<0.001
Phase 3 N=304 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Bladder Cancer
Primary: Proportion of Patients With Histologically Confirmed Malignancy Where Malignancy is Only Detected With Blue Light Cystoscopy With Cysview and Not White Light Cystoscopy…
Phase 4 N=5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis · Anterior Uveitis · Intermediate Uveitis
Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants
Phase 2 N=413 Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Hepatitis C
Primary: Percentage of HCV GT3-infected Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) — 90.5; 95.2; 86.4; 90.9 Percentage of participants
Phase 3 N=7 An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
Epilepsy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Perampanel — 6; 0; 0…